JP2008133278A5 - - Google Patents

Download PDF

Info

Publication number
JP2008133278A5
JP2008133278A5 JP2007300664A JP2007300664A JP2008133278A5 JP 2008133278 A5 JP2008133278 A5 JP 2008133278A5 JP 2007300664 A JP2007300664 A JP 2007300664A JP 2007300664 A JP2007300664 A JP 2007300664A JP 2008133278 A5 JP2008133278 A5 JP 2008133278A5
Authority
JP
Japan
Prior art keywords
group
substituent
atom
salt
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007300664A
Other languages
English (en)
Japanese (ja)
Other versions
JP4931775B2 (ja
JP2008133278A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2007300664A priority Critical patent/JP4931775B2/ja
Priority claimed from JP2007300664A external-priority patent/JP4931775B2/ja
Publication of JP2008133278A publication Critical patent/JP2008133278A/ja
Publication of JP2008133278A5 publication Critical patent/JP2008133278A5/ja
Application granted granted Critical
Publication of JP4931775B2 publication Critical patent/JP4931775B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007300664A 2004-08-06 2007-11-20 芳香族化合物 Expired - Fee Related JP4931775B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007300664A JP4931775B2 (ja) 2004-08-06 2007-11-20 芳香族化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2004230092 2004-08-06
JP2004230092 2004-08-06
JP2005090149 2005-03-25
JP2005090149 2005-03-25
JP2007300664A JP4931775B2 (ja) 2004-08-06 2007-11-20 芳香族化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005229066A Division JP4154613B2 (ja) 2004-08-06 2005-08-08 芳香族化合物

Publications (3)

Publication Number Publication Date
JP2008133278A JP2008133278A (ja) 2008-06-12
JP2008133278A5 true JP2008133278A5 (enExample) 2008-09-18
JP4931775B2 JP4931775B2 (ja) 2012-05-16

Family

ID=35508545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005229066A Expired - Fee Related JP4154613B2 (ja) 2004-08-06 2005-08-08 芳香族化合物
JP2007300664A Expired - Fee Related JP4931775B2 (ja) 2004-08-06 2007-11-20 芳香族化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2005229066A Expired - Fee Related JP4154613B2 (ja) 2004-08-06 2005-08-08 芳香族化合物

Country Status (16)

Country Link
US (2) US8188277B2 (enExample)
EP (1) EP1773797A2 (enExample)
JP (2) JP4154613B2 (enExample)
KR (1) KR100927563B1 (enExample)
CN (1) CN1993339B (enExample)
AR (1) AR050448A1 (enExample)
AU (1) AU2005268030B2 (enExample)
BR (1) BRPI0514150A (enExample)
CA (1) CA2573223C (enExample)
IL (1) IL180884A (enExample)
MX (1) MX2007001215A (enExample)
MY (1) MY148905A (enExample)
RU (1) RU2416608C2 (enExample)
TW (1) TWI353983B (enExample)
WO (1) WO2006014012A2 (enExample)
ZA (1) ZA200700811B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188277B2 (en) 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
KR20080016649A (ko) 2005-06-16 2008-02-21 화이자 인코포레이티드 Ｎ-(피리딘-2-일)-술폰아미드 유도체
PL1940786T3 (pl) 2005-09-16 2010-12-31 Arrow Therapeutics Ltd Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
EP1957073B1 (en) 2005-12-05 2014-04-23 Otsuka Pharmaceutical Co., Ltd. Medicinal drug
JP5142513B2 (ja) * 2005-12-05 2013-02-13 大塚製薬株式会社 医薬
WO2007067444A1 (en) 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
JP5420395B2 (ja) 2006-04-07 2014-02-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセット輸送体の調節剤
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
ES2498043T3 (es) * 2006-06-06 2014-09-24 Cornerstone Therapeutics Inc. Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas
US7943622B2 (en) 2006-06-06 2011-05-17 Cornerstone Therapeutics, Inc. Piperazines, pharmaceutical compositions and methods of use thereof
NZ574028A (en) 2006-07-05 2010-10-29 Fibrotech Therapeutics Pty Ltd Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis
ES2396715T3 (es) 2006-08-21 2013-02-25 Array Biopharma, Inc. Derivados de ácido fenoxifenilacético 4-sustituido
US8030324B2 (en) * 2006-09-21 2011-10-04 Piramal Life Sciences Ltd. Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
AU2012202382B2 (en) * 2006-10-02 2014-06-26 Otsuka Pharmaceutical Co., Ltd. STAT3/5 activation inhibitor
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US20090023731A1 (en) * 2007-03-22 2009-01-22 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
EP2164840A2 (en) 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
JP2010536839A (ja) * 2007-08-17 2010-12-02 アストラゼネカ アクチボラグ 化合物９７９
CA2989620C (en) 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
HUE049642T2 (hu) 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
CA2716109C (en) 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
BRPI0921299A2 (pt) 2008-11-21 2015-08-25 High Point Pharmaceuticals Llc Compostos de benzamida adamantila
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
JP5688918B2 (ja) * 2009-04-28 2015-03-25 大塚製薬株式会社 医薬組成物
ES2749504T3 (es) 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
EP2947073B1 (en) * 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
PH12012501532A1 (en) 2010-01-29 2012-10-22 Otsuka Pharma Co Ltd Di-substituted pyridine derivatives as anticancers
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
NZ609151A (en) 2010-10-04 2015-01-30 Otsuka Pharma Co Ltd 4-(methylaminophenoxy)pyridin-3-yl-benzamide derivatives for treating cancer
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
EA027810B1 (ru) 2012-08-31 2017-09-29 НОВАДРАГ, ЭлЭлСи Гетероциклические карбоксамиды для лечения вирусных заболеваний
NZ716598A (en) * 2012-11-20 2017-02-24 Merial Inc Anthelmintic compounds and compositions and method of using thereof
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
PL3925607T5 (pl) 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
NZ726874A (en) * 2014-05-19 2018-03-23 Merial Inc Anthelmintic compounds
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
EP3577103A1 (en) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
JP7444458B2 (ja) * 2018-09-21 2024-03-06 学校法人福岡大学 プリオン病治療薬
CN111847474B (zh) * 2020-07-17 2021-09-28 浙江恒澜科技有限公司 一种Ti-ITQ-24沸石分子筛及其原位合成方法和应用
JP2025510009A (ja) * 2022-02-28 2025-04-14 シロナックス リミテッド． Ｒｉｐ１調節物質、その調製、及び使用
CN118206542B (zh) * 2023-03-22 2025-06-27 沈阳药科大学 一种化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用
CN117843521A (zh) * 2024-01-02 2024-04-09 中国药科大学 一种作为甲状腺激素β受体激动剂的化合物及其制备方法、应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629102A (enExample) * 1961-03-29
US3715375A (en) 1970-09-17 1973-02-06 Merck & Co Inc New diphenyl sulfones
NL7111711A (enExample) 1970-09-17 1972-03-21
GB1494117A (en) 1974-11-02 1977-12-07 Bayer Ag Process for the preparation of acid amides
DE2707659A1 (de) 1977-02-23 1978-08-24 Bayer Ag Selbstvernetzbare polyurethane
DE2707660C2 (de) 1977-02-23 1985-12-19 Bayer Ag, 5090 Leverkusen Abspalter- und Diolrest enthaltende Diisocyanat-Addukte, ihre Herstellung und Verwendung
DE2812252A1 (de) 1978-03-21 1979-10-04 Bayer Ag 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
EP0500495A3 (en) 1991-02-21 1993-04-07 Ciba-Geigy Ag Thermosetting composition
EP0580550B1 (en) 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
JP3894949B2 (ja) 1993-06-30 2007-03-22 ザ、ウェルカム、ファンデーション、リミテッド 抗アテローム性動脈硬化症ジアリール化合物
AU702423B2 (en) 1995-06-07 1999-02-18 Institute Of Materia Medica Chalcone retinoids and methods of use of same
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
EP1060171A2 (de) 1998-02-06 2000-12-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase-inhibitoren
ES2233025T3 (es) 1998-02-06 2005-06-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Agente inhibidores de la triptasa.
AR015733A1 (es) 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
TWI245035B (en) 1998-06-26 2005-12-11 Ono Pharmaceutical Co Amino acid derivatives and a pharmaceutical composition comprising the derivatives
KR100682276B1 (ko) 1998-07-24 2007-02-28 데이진 가부시키가이샤 안트라닐산 유도체
WO2000015603A1 (en) * 1998-09-11 2000-03-23 Ajinomoto Co., Inc. Benzene derivatives and medicinal use thereof
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1150955A2 (en) 1999-02-04 2001-11-07 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6159694A (en) * 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
EP1193255A4 (en) 1999-07-01 2002-08-07 Ajinomoto Kk HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN MEDICINE
JP2001089412A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
JP2001089450A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ピリジン誘導体含有医薬製剤
AU2001234089B2 (en) 2000-02-15 2005-08-11 Teijin Limited Cancer remedy comprising anthranilic acid derivative as active ingredient
DZ3347A1 (fr) 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
AU2001282874A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
IL155097A0 (en) 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
EP1211235A3 (en) 2000-11-30 2004-01-02 JFE Chemical Corporation Preparation process of 4,4'-Dicarboxydiphenyl ethers or derivatives thereof
JP2004269356A (ja) 2000-12-27 2004-09-30 Ajinomoto Co Inc 創傷部癒着防止剤
GB2374009A (en) 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
HUP0400369A2 (hu) 2001-06-20 2004-12-28 Pfizer Products Inc. Új szulfonsavszármazékok és ezeket tartalmazó gyógyszerkészítmények
MXPA04000779A (es) 2001-08-24 2004-04-20 Pharmacia & Up John Company 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades.
EP1438298B1 (en) 2001-10-22 2010-01-27 Pfizer Products Inc. Piperazine derivatives with ccr1 receptor antagonist activity
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
US6852716B2 (en) 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
JP2004035475A (ja) 2002-07-03 2004-02-05 Ajinomoto Co Inc ＴＧＦβ作用抑制剤
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
RU2396250C2 (ru) 2003-07-24 2010-08-10 Лео Фарма А/С Новые производные аминобензофенона
US8188277B2 (en) 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
EP1957073B1 (en) 2005-12-05 2014-04-23 Otsuka Pharmaceutical Co., Ltd. Medicinal drug
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物

Similar Documents

Publication Publication Date Title
JP2007231005A5 (enExample)
AU2006323700B2 (en) Diarylether derivatives as antitumor agents
JP2007508359A5 (enExample)
JP2009541403A5 (enExample)
RU2008146088A (ru) Оксадиазолидиндионовое соединение
JP2012520247A5 (enExample)
JP2010535722A5 (enExample)
JP2009543867A5 (enExample)
WO2003057688A3 (en) Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
JP2011137006A5 (enExample)
ATE516326T1 (de) Kautschukmischungen
JP2007508362A5 (enExample)
JP2009535358A5 (enExample)
JP2005523310A5 (enExample)
JP2010536766A5 (enExample)
JP2010504286A5 (enExample)
JP2004530641A5 (enExample)
JP2008525417A5 (enExample)
JP2007246474A5 (enExample)
WO2001087845A3 (en) N-containing heterocyclic compounds and their use as 5-ht antagonists
JP2010504930A5 (enExample)
JP2010536821A5 (enExample)
WO2007081569A3 (en) Cetp inhibitors
JP2007506721A5 (enExample)
JP2007519618A5 (enExample)